Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

References

• Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
   PubMed Web of Science ®Google Scholar
• Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
   PubMed Web of Science ®Google Scholar
• Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4(exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
   PubMed Web of Science ®Google Scholar
• Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003;4:401-5
   PubMedGoogle Scholar
• Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-9
   PubMed Web of Science ®Google Scholar
• Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-34
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009;11:1122-30
   PubMed Web of Science ®Google Scholar
• Brixner DI, McAdam-Marx C, Ye X, et al. Real-world six month outcomes of patients initiating exenatide in a primary care electronic medical record database [ISPOR abstract DB1]. Value Health 2008;11(Suppl):A17
   Google Scholar
• Brixner DI, McAdam-Marx C, Ye X, et al. 18 month A1C and weight outcomes of exenatide therapy in patients with type-2 diabetes in a real-world study [ISPOR abstract PDB6]. Value Health 2009;12(Suppl):A97
   Google Scholar
• Fabunmi R, McAdam-Marx C, Ye X, et al. Blood pressure outcomes after 6 months of exenatide treatment in patients with type 2 diabetes in a real world study [ADA abstract 470-P]. Diabetes 2009;58(Suppl 1):A125
   PubMedGoogle Scholar
• McAdam-Marx C, Brixner DI, Ye X, et al. A1C and weight outcomes following 6 months of analog basil insulin in insulin-naïve patients with type 2 diabetes in an ambulatory care setting [ISPOR abstract PDB2]. Value Health 2009;12(Suppl):A97
   Google Scholar
• Wade R, Quimbo R, Fabunmi R, et al. Utilization patterns and hypoglycemia in patients with type 2 diabetes on concomitant exenatide and long-acting insulin therapy [ISPOR abstract PDB15]. Value Health 2009;12(Suppl):A99
   Google Scholar
• Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Garrison LP, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin 2011;27:531-40
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes – 2007. Diabetes Care 2007;30(Suppl 1):S4-41
   PubMedGoogle Scholar
• Washington MC, Raboin SJ, Thompson W, et al. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res 2010;16:124-33
   Google Scholar
• Joy SV, Rodgers PT, Scates AC. New drug developments: incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005;39:110-18
   PubMed Web of Science ®Google Scholar
• Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
   PubMed Web of Science ®Google Scholar
• Exenatide (Byetta) injection prescribing information. Amylin Pharmaceuticals, Inc., 2005
   Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar